Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
866 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
3 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
4 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
5 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
6 Recruiting Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Erlotinib;   Biological: Ipilimumab
7 Recruiting Detection of Genetic Markers of Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Procedure: Biopsy of the major carinal area;   Procedure: Biopsy of abnormal & suspicious areas of the bronchial tree;   Procedure: Evaluation of the tumor for DNA mutations;   Procedure: Bronchoalveolar Lavage (BAL) for cytokine analysis;   Procedure: Correlation of flow cytometric & RT PCR for TNM stage;   Procedure: Analysis of lymph nodes
8 Recruiting Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo;   Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream;   Drug: Dacomitinib
9 Recruiting Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
10 Recruiting Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)
Condition: Non-small Cell Lung Cancer Patients
Intervention: Procedure: 18F-FDG-PET scan
11 Recruiting Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
Condition: Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: Pembrolizumab 200 mg every 3 weeks
12 Recruiting PKCi & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer
Conditions: Adenosquamous Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sirolimus;   Drug: auranofin
13 Unknown  Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Conditions: Non Small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Gefitinib;   Drug: Placebo;   Drug: Pemetrexed plusCIsplatin
14 Recruiting Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Condition: Non Small Cell Lung Cancer
Interventions: Procedure: Stereostatic Radiosurgery;   Drug: Erlotinib
15 Not yet recruiting The Effect Of Aspirin On Survival in Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Survival;   Aspirin
Interventions: Drug: Aspirin 75 mg;   Other: no aspirin
16 Unknown  Non-Small Cell Lung Cancer and Quality of Life
Condition: Non Small Cell Lung Cancer
Intervention:
17 Unknown  Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Interventions: Radiation: radiotherapy combined with EP;   Drug: radiotherapy / EP combined with recombinant human endostatin
18 Unknown  Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: cisplatin and gemcitabine combination with Bevacizumab;   Drug: Gemcitabine combined with cisplatin chemotherapy
19 Recruiting Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy
Condition: Extensive Stage Small Cell Lung Carcinoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
20 Recruiting Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
Condition: Non Small Cell Lung Cancer
Intervention: Drug: erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years